NEW YORK (GenomeWeb) — BGI and Maxwell Plus announced this week that they have partnered to develop a risk model to predict the likelihood a prostate cancer patient will develop advanced or metastatic disease.

Under the terms of the deal, the companies will use Brisbane, Australia-based Maxwell's artificial intelligence technology to analyze data from patient samples sequenced on BGI's MGISEQ-2000 instrument. The sequencing will be carried out at Shenzhen, China-based BGI's Australian lab. Additional terms were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.